• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Corvert Injection (ibutilide fumarate injection)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Corvert Injection (ibutilide fumarate injection)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Covert Injection was approved to treat atrial fibrillation and atrial flutter, two common arrhythmias that cause irregular contractions of the heart. Covert is indicated for the rapid conversion of atrial fibrillation or atrial flutter to normal sinus rhythm.

    Clinical Results

    The results of two, large, placebo-controlled, double-blind and randomized clinical trials demonstrated that, compared with placebo, Corvert Injection successfully and rapidly converted atrial fibrillation and flutter to normal rhythm. In a third study conducted in Europe, Covert compared favorably with another intravenous antiarrhythmic agent currently unavailable in the United States

    Side Effects

    A small number of subjects (1.7%) treated with Covert developed sustained polymorphic ventricular tachycardia (PVT), an arrhythmia of the ventricles. This side effect is common to antiarrhythmic agents used to treat atrial fibrillation and flutter and is potentially life threatening. However, the small number of subjects who developed PVT were successfully treated with electrical cardioversion.

    Additional Information

    The atria are the upper chambers of the heart. They receive blood from the body and lungs; they load the ventricles, the primary pumping chambers of the heart; and they regulate, with electrical currents, the pace of contraction (heart beat) for the entire heart. Atrial fibrillation and flutter are common arrhythmias that cause irregular contractions of the heart. Alone, the conditions are not considered life-threatening. But they can lead to decreased cardiac output, congestive heart failure and low blood pressure in some subjects. Atrial fibrillation is a risk factor for embolic stroke. Prevalence of these arrhythmias increases with age. Atrial fibrillation affects 0.4% of Americans under the age of 60 and 2% to 4% of those over 60 years of age.

    Electrical cardioversion is the primary treatment option for subjects who would benefit from rapid conversion of atrial fibrillation and flutter to normal sinus rhythm. The procedure, which delivers an electrical current to the heart, requires anesthesia to minimize subject discomfort.

    Approval Date: 1995-12-01
    Company Name: Pharmacia & Upjohn
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing